Synthorx lines up some big synthetic biology R&D goals after grabbing a $10M round
Synthetic biology offers some dramatic possibilities in the drug development world. And now one of the upstart pioneers in the field of synthetic life has picked up a notable $10 million round to attempt a breakout move using artificial proteins in preclinical development.
Synthorx’s B round won’t rank in size as a standout in a big venture year like 2016. But if it’s right, and the science works as billed, the developer will use its cash over the next three years to line up the first clinical programs that will attempt to create entirely new therapeutic proteins and peptides by tinkering with the collection of amino acids that are used by nature to build them.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
